In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin
- PMID: 15491997
- DOI: 10.1074/jbc.M409783200
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin
Abstract
Recombinant immunotoxin BL22, containing the Fv portion of an anti-CD22 antibody, produced complete remissions in most patients with drug-resistant hairy cell leukemia but had less activity in leukemias with low CD22 expression. Complementarity-determining region (CDR) mutagenesis is used to increase antibody affinity but can be difficult to perform successfully. We previously showed that antibodies with increased affinity and immunotoxins with increased activity could be obtained by directing mutations at specific DNA residues called hot spots. Because hot spots can arise either by somatic mutation or be present in the germline, we examined which type of hot spot is preferred for increasing antibody affinity. Initially, a second generation antibody phage-display library targeting a germline hot spot (Ser(30)-Asn(31)) within CDR1 of the antibody light chain was mutated. Substitution of serine 30 or asparagine 31 with arginine produced mutant immunotoxins with an affinity (0.8 nM) increased 7-fold over BL22 (5.8 nM) and 3-fold over the first generation mutant HA22 (2.3 nM). More importantly, a 10-fold increase in activity over BL22 and a 2-3-fold increase over HA22 were observed in various B lymphoma cell lines including WSU-CLL that contains only 5500 CD22 sites per cell. For comparison, two phage-display libraries targeting non-germline hot spots in heavy chain CDR1 and CDR3 were generated but did not produce Fv with increased affinity. Our results demonstrate that germline hot spots but not non-germline hot spots are effective for in vitro antibody affinity maturation.
Similar articles
-
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.Clin Cancer Res. 2002 Apr;8(4):995-1002. Clin Cancer Res. 2002. PMID: 11948105
-
HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.Clin Cancer Res. 2005 Feb 15;11(4):1545-50. doi: 10.1158/1078-0432.CCR-04-1939. Clin Cancer Res. 2005. PMID: 15746059
-
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins.Blood. 2004 Apr 1;103(7):2718-26. doi: 10.1182/blood-2003-04-1317. Epub 2003 Oct 2. Blood. 2004. PMID: 14525789
-
Recombinant immunotoxins for treating cancer.Int J Med Microbiol. 2004 Apr;293(7-8):577-82. doi: 10.1078/1438-4221-00302. Int J Med Microbiol. 2004. PMID: 15149034 Review.
-
Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):79-86. doi: 10.1016/s1040-8428(01)00116-0. Crit Rev Oncol Hematol. 2001. PMID: 11418304 Review.
Cited by
-
Molecular engineering of antibodies for therapeutic and diagnostic purposes.MAbs. 2012 Jul-Aug;4(4):445-57. doi: 10.4161/mabs.20776. Epub 2012 Jul 1. MAbs. 2012. PMID: 22684311 Free PMC article. Review.
-
A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer.Mol Ther Oncolytics. 2022 Feb 20;24:849-863. doi: 10.1016/j.omto.2022.02.015. eCollection 2022 Mar 17. Mol Ther Oncolytics. 2022. PMID: 35317524 Free PMC article.
-
Hairy cell leukemia-new genes, new targets.Curr Hematol Malig Rep. 2013 Sep;8(3):184-95. doi: 10.1007/s11899-013-0167-0. Curr Hematol Malig Rep. 2013. PMID: 23892906 Free PMC article. Review.
-
An immunodominant La/SSB autoantibody proteome derives from public clonotypes.Clin Exp Immunol. 2013 Nov;174(2):237-44. doi: 10.1111/cei.12171. Clin Exp Immunol. 2013. PMID: 23841690 Free PMC article.
-
CAR-T cells based on a TCR mimic nanobody targeting HPV16 E6 exhibit antitumor activity against cervical cancer.Mol Ther Oncol. 2024 Oct 9;32(4):200892. doi: 10.1016/j.omton.2024.200892. eCollection 2024 Dec 19. Mol Ther Oncol. 2024. PMID: 39524212 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources